Phase 3RecruitingNCT07222332
BARICADE-PRESERVE: Baricitinib in newly diagnosed T1D
Phase-3 trial testing baricitinib in children and adults newly diagnosed with stage-3 T1D, following the positive BANDIT phase-2 result.
Primary endpoints
- Change in C-peptide AUC at 52 weeks
Results so far
No results posted as of the June 2026 registry update reviewed here.
The full picture
BARICADE-PRESERVE is the phase-3 confirmation test for baricitinib's new-onset beta-cell-preservation signal.